Synlogic Inc (NASDAQ:SYBX) Expected to Announce Earnings of -$0.46 Per Share

Brokerages expect that Synlogic Inc (NASDAQ:SYBX) will report ($0.46) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Synlogic’s earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.40). Synlogic posted earnings of ($0.43) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Synlogic will report full year earnings of ($1.90) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($1.75). For the next fiscal year, analysts forecast that the company will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.60) to ($1.73). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Synlogic.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.04. The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. Synlogic had a negative return on equity of 34.75% and a negative net margin of 1,844.96%.

A number of analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on Synlogic in a research report on Tuesday, April 30th. They issued a “buy” rating and a $18.00 target price for the company. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Synlogic in a research report on Friday, August 9th. ValuEngine raised Synlogic from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Oppenheimer downgraded Synlogic from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $20.00 price target (up previously from $10.00) on shares of Synlogic in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. Synlogic presently has an average rating of “Buy” and an average target price of $16.33.

Hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in Synlogic by 50.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock valued at $2,220,000 after acquiring an additional 105,628 shares during the last quarter. BlackRock Inc. boosted its holdings in Synlogic by 33.4% in the fourth quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock valued at $8,750,000 after acquiring an additional 312,398 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Synlogic by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock valued at $1,087,000 after acquiring an additional 16,591 shares during the last quarter. Northern Trust Corp boosted its holdings in Synlogic by 1.2% in the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after acquiring an additional 2,005 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in Synlogic by 5,743.1% in the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 12,520 shares during the last quarter. Institutional investors and hedge funds own 66.08% of the company’s stock.

Shares of NASDAQ SYBX traded down $0.10 during trading hours on Thursday, reaching $3.13. The stock had a trading volume of 553,399 shares, compared to its average volume of 136,932. The firm has a market cap of $153.20 million, a price-to-earnings ratio of -1.55 and a beta of 2.39. The company has a current ratio of 14.43, a quick ratio of 14.43 and a debt-to-equity ratio of 0.13. Synlogic has a fifty-two week low of $2.90 and a fifty-two week high of $14.59. The firm has a 50-day moving average of $6.41 and a 200-day moving average of $7.80.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Recommended Story: Why are percentage decliners important?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.